Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious ascites from patient that had no chemotherapy prior to surgery
| Inventor | Institute |
|---|---|
| Anne-Marie Mes-Masson and Diane Provencher | Centre Hospitalier de Luniversité de Montréal |
| SKU: | 161787 |
|---|---|
| Product description: | Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious ascites from patient that had no chemotherapy prior to surgery. Patient received radiotherapy and hormonotherapy for breast cancer five year prior to ovarian cancer diagnosis. |
| Alternate name: | OV-4453 |
| Gender: | Female |
| CRISPR: | No |
| Production details: | Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly. |
| Additional notes: | Patient 4453 was age 70 at diagnosis, BRCA hereditary status was BRCA2(+), and had previous history of breast cancer. Treatment for ovarian cancer included Carboplatin/taxol and interval surgery. Year of sampling was 2009. |
| Cellosaurus ID: | CVCL_9T20 |
| Receptors of note: | No |
| Cat. #: | 161787 |
|---|---|
| Cancer types: | Ovarian cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Derived from ascites from patient with high grade serous carcinoma |
| Gender: | Female |
| Morphology: | Formed numerous individual small aggregates |
| Growth properties: | Adherent |
| Primary citation: | Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941 |
| Growth medium: | OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin |
|---|---|
| Atmosphere: | Low oxygen conditions of 7% O2 and 5% CO2 |
| References: |
Vias et al. 2023. Elife. 11,12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16,14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30 15(9):2566. PMID: 37174032 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.